[Clinical considerations on the use of an antispastic-antivagal drug association in the cholecysto-coronary syndrome].
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D001535:Benactyzine / Q000008:administration & dosage / Q000627:therapeutic use*; D001660:Biliary Tract Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010417:Pentaerythritol Tetranitrate / Q000008:administration & dosage / Q000627:therapeutic use*; D011343:Procaine / Q000008:administration & dosage / Q000627:therapeutic use*; D013577:Syndrome; D013806:Theophylline / Q000008:administration & dosage / Q000627:therapeutic use*; D014149:Tranquilizing Agents / Q000627:therapeutic use
D004338:Drug Combinations; D014149:Tranquilizing Agents; D010417:Pentaerythritol Tetranitrate; D011343:Procaine; D001535:Benactyzine; D013806:Theophylline
Considerazioni cliniche sull'impiego di una associazione antispastica antivagale nella sindrome colecisto-coronarica.